The bill amends K.S.A. 2024 Supp. 65-16,131 to expand the scope of practice for pharmacists in Kansas, allowing them to initiate therapy for COVID-19 alongside existing conditions such as influenza, streptococcal pharyngitis, and urinary tract infections. The collaborative drug therapy management advisory committee is tasked with establishing statewide protocols for these health conditions, which will include specifications on medications, training requirements for pharmacists, documentation standards, and communication protocols with patients' primary care providers.

Additionally, the bill includes a provision that allows the state board of pharmacy to deny, revoke, or suspend a pharmacist's license if they violate the established protocols. The existing section of K.S.A. 2024 Supp. 65-16,131 is repealed, and the new provisions will take effect upon publication in the statute book.

Statutes affected:
As introduced: 65-16